A Double-Blind, Placebo-Controlled Study to Establish the Safety and Efficacy of Super-Concentrated, Freeze-Dried Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

The purpose of this study is to assess the safety and efficacy of super-concentrated, freeze-dried aloe vera capsules for treatment of interstitial cystitis.

Start Date18 Feb 2025

Sponsor / Collaborator

Wake Forest School of Medicine

[+1]

IRCT20191106045356N21

/ RecruitingPhase 3IIT

Formulation of a topical gel containing Lawsonia inermis extract and Aloe vera and evaluation its effects on the healing process of second degree burns: A randomized double_blinded placebo_controlled trial.

Start Date21 Oct 2024

Sponsor / Collaborator-

CTRI/2024/09/073897

/ Not yet recruitingNot ApplicableIIT

Effects of topical application of urea and aloe vera cream on hand-foot syndrome in GI cancer patients receiving 5FU. A randomized controlled trail. - NIL

Start Date30 Sep 2024

Sponsor / Collaborator

Tata Memorial Centre

100 Clinical Results associated with Aloe vera extract

100 Translational Medicine associated with Aloe vera extract

100 Patents (Medical) associated with Aloe vera extract

355

Literatures (Medical) associated with Aloe vera extract

01 May 2026·European journal of dentistry

Evaluation of the Antifungal Efficacy of Natural Gum Acacia and Aloe Vera against Candida albicans on Conventional and Digital Denture Base Materials: An In Vitro Study

Article

Author: El-Din, Mai Salah ; Zeitoun, Hend ; Moussa, Rania ; Alqutaibi, Ahmed Yaseen ; Al-Gabri, Redhwan Saleh ; Zafar, Muhammad Sohail ; Fayad, Mostafa I.

Abstract:

This study evaluated the efficacy of Acacia Arabica and aloe vera solutions versus commercial effervescent tablets on Candida viability and adhesion to various denture bases with different materials and manufacturing techniques.A total of 96 square-shaped denture base specimens (24 per group) were fabricated from heat-cured polymethyl methacrylate (PMMA), thermoformed polyamide (FlexiUltra), milled computer-aided design and computer-aided manufacturing (CAD/CAM; Avadent), and 3D-printed (FormLabs) resins. Specimens were allocated into a control group (distilled water) and three experimental groups (n = 6 per group) based on the immersion solutions: Gum acacia (GA), aloe vera, and alkaline peroxide denture cleansers. One specimen from each material subgroup was prepared for qualitative assessment. All specimens were incubated with Candida albicans for 48 hours and immersed in the designated disinfectant solution for 8 hours. Anti-C. albicans biofilm activity was assessed quantitatively using an MTT assay and qualitatively using a confocal laser scanning microscope (CLSM).One-way analysis of variance (ANOVA) was employed for mean comparison, and data were considered significant at p < 0.05.The reduction in mean Candida viability was greatest in the alkaline peroxide tablets across all denture base materials, followed by GA and aloe vera (p < 0.001). GA demonstrated a statistically significant reduction in Candida levels in the thermoplastic polyamide (p < 0.001). The mean viability of Candida in both alkaline peroxide tablets and GA was statistically similar in digital denture bases (p > 0.05).The antifungal efficacy of alkaline peroxide denture cleansers was determined to be the highest. The cost-effective GA may serve as a viable denture disinfectant, particularly for thermoformed polyamide denture bases.

01 May 2026·International Journal of Dental Hygiene

Clinical Assessment of the Efficacy of Natural Nutraceuticals in Gingival Massage Therapy: A Randomized Clinical Study

Article

Author: Pervaiz, Haseeb ; Khalid, Fizza ; Farooqui, Waqas Ahmed ; Khan, Ziaur Rahman ; Ahmed, Shahbaz ; Ghazal, Mehwish ; Shabbir, Sumaiya ; Riaz, Sania

ABSTRACT:

Objective:

The purpose of this randomized clinical trial was to assess the efficacy of gingival massage therapy with Aloe vera gel and sidr honey and to find out the difference in their efficacies, in reducing clinical parameters in gingival inflammation.

Method:

Participants with gingivitis were selected in this randomised clinical trial (RCT). Scaling and root debridement (SRD) was performed and baseline plaque index (PI), gingival index (GI) and bleeding on probing (BOP) were recorded and participants were randomly allocated into three groups. Group A: SRD and gingival massage (GM) with Aloe vera gel, Group B: SRD and GM with Sidr honey and Group C: SRD only. On the 30th day all clinical parameters were re‐evaluated.

Results:

Gingival massage therapy with both interventions showed improvement in all clinical parameters, when used as an adjunct to non‐surgical periodontal therapy. Aloe vera versus control showed improvements in PI (−0.57) and GI (−0.32); honey versus control in PI (−0.68) and GI (−0.63) and Aloe vera versus honey in PI (0.11) and GI (−0.57). BOP was also reduced in all three groups.

Conclusion:

This ClinicalTrial showed that gingival massage therapy with Aloe vera gel and sidr honey was effective in reducing plaque index, gingival index and bleeding on probing when used as adjuncts in patients with gingivitis. However, group B was more effective when compared with group A and group C. Future RCTs will further evaluate the synergistic effects of these adjuncts in periodontal treatments.

Trial Registration:

ClinicalTrials.gov identifier: NCT05231096

01 Apr 2026·SAUDI PHARMACEUTICAL JOURNAL

Therapeutic potential of Aloe vera in diabetes mellitus treatment: an update

Review

Author: Ahmad, Matloob ; Adil, Muhammad ; Akram, Sumayya ; Zaki, Magdi E A

Abstract:

Diabetes mellitus is a metabolic disease manifested by hyperglycemia, leading to critical health challenges in the kidneys, eyes, nerves, and cardiovascular system. Aloe vera ( Aloe barbadensis miller ), a traditionally used herbal plant for treating various diseases, contains abundant bioactive compounds like alkaloids, flavonoids, acemannans, anthraquinones, chromones, anthrones, enzymes, vitamins, and minerals. These compounds are responsible for its diverse biological activities, including antimicrobial, anticancer, antidiabetic, anti-inflammatory, antioxidant, and hypolipidemic etc. This review primarily focuses on diabetes treatment through enzyme inhibition and modulation of metabolic parameters, with additional emphasis on diabetic complications including, the wound healing efficacy of Aloe vera . This study aims to evaluate the potential of Aloe vera in managing diabetes and minimizing the chances of diabetes-related organ damage. It was done by inhibition of several enzymes, including α -glucosidase, α -amylase, dipeptidyl peptidase-4, pancreatic lipase, sucrase, and maltase enzymes, both in vivo and in vitro. The previous research revealed that administrating various doses of Aloe vera -based extracts via orally and non-orally routes in streptozotocin-induced diabetes offered metabolic regulation of signaling pathways like blood sugar, insulin, lipid profile, body weight, oxidative stress, TNF- α , and IL-6 levels. Moreover, clinical data have confirmed Aloe vera ’s potential in diabetic wound healing by promoting tissue regeneration mechanisms like angiogenesis, fibrinogenesis, collagen synthesis, and inflammation to reduce lesion size. These therapeutic properties highlight the hypoglycemic nature of Aloe vera , promising its potential for future clinical use as an alternative for diabetes treatment. Graphical Abstract

News (Medical) associated with Aloe vera extract

08 Feb 2026

·www.sciencedaily.com

A hidden Aloe vera compound takes aim at Alzheimer’s

Scientists have uncovered promising clues that compounds found in Aloe vera could play a role in fighting Alzheimer’s disease. Using advanced computer modeling, researchers discovered that beta-sitosterol—a natural plant compound—strongly interacts with two key enzymes involved in memory loss and cognitive decline. The compound showed stability, strong binding, and favorable safety indicators, making it a standout candidate for future drug development.Scientists are continuing to search for new ways to treat Alzheimer's disease (AD), a progressive brain disorder that affects memory, thinking, and behavior. In a recent study, researchers identified several compounds found in Aloe vera that could offer new possibilities for future treatments. Aloe vera is best known as a soothing plant used for skin care, but it also contains natural chemicals that may influence biological processes inside the body. The study, published in Current Pharmaceutical Analysis, focused on how these plant compounds interact with key enzymes involved in Alzheimer's disease. Using computer-based research methods, scientists examined whether Aloe vera compounds could interfere with processes linked to the breakdown of brain signaling in people with AD. Key Enzymes Linked to Memory Loss The research centered on two enzymes called acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). These enzymes play an important role in breaking down acetylcholine, a chemical messenger that helps nerve cells communicate. In Alzheimer's disease, acetylcholine levels are already reduced, which contributes to memory loss and cognitive decline. Medications that slow down these enzymes can help preserve acetylcholine and improve symptoms in some patients. To study this process, researchers used in silico methods, which rely on computer simulations rather than laboratory experiments. These methods allow scientists to predict how molecules might behave inside the body before moving on to real world testing. "Our findings suggest that Beta sitosterol, one of the Aloe vera compounds, exhibits significant binding affinities and stability, making it a promising candidate for further drug development," said Meriem Khedraoui, the lead author of the study. How Computer Models Test Drug Potential The team used molecular docking and molecular dynamics simulations to see how different Aloe vera compounds attach to AChE and BChE. Molecular docking helps predict how well a compound fits into an enzyme, while molecular dynamics simulations examine how stable that interaction remains over time. Among all the compounds tested, Beta sitosterol stood out. It showed binding affinities of −8.6 kcal/mol with AChE and −8.7 kcal/mol with BChE, meaning it attached more strongly to both enzymes than other compounds tested, including Succinic acid. Strong binding suggests the compound may be effective at slowing enzyme activity. "These results highlight the potential of Beta sitosterol as a dual inhibitor, which could be crucial in managing Alzheimer's disease," said Khedraoui. Evaluating Safety and Drug Behavior in the Body In addition to enzyme binding, the researchers also examined whether the compounds might be safe and effective if used as medications. This was done using ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis. ADMET testing helps predict how a compound enters the body, how it spreads through tissues, how it is broken down, how it is removed, and whether it could cause harmful side effects. The analysis showed that both Beta sitosterol and Succinic acid had favorable pro suggesting they could be absorbed well and are unlikely to be toxic at therapeutic levels. "The comprehensive analysis supports the potential of these compounds as safe and effective therapeutic agents," said Samir Chtita, another author of the study. Next Steps Toward Alzheimer's Treatments While the findings are encouraging, the researchers emphasize that the work is still in its early stages. Because the study relied on computer simulations, laboratory experiments and clinical trials will be needed to confirm whether these compounds are effective and safe in real patients. Even so, the study provides an important foundation for future research into plant based therapies for Alzheimer's disease. "Our in silico approach offers a promising direction for the development of novel treatments for Alzheimer's disease," said Khedraoui.

Clinical Result

28 Aug 2025

·www.prnewswire.com

DermaRite Industries Expands Voluntary Nationwide Recall Due to Potential Burkholderia cepacia Contamination

NORTH BERGEN, N.J., Aug. 27, 2025 /PRNewswire/ -- DermaRite Industries, LLC is expanding the voluntary recall initiated on July 16, due to potential microbial contamination identified as Burkholderia cepacia complex. Out of an abundance of caution the voluntary recall has expanded to include additional products and lots, which can be found in the table below. Please see DermaRite.com for the original recall notice. Risk Statement: Burkholderia cepacia complex in these products may result in serious and life-threatening infections if the products are used by immunosuppressed individuals or by people attending to immunosuppressed individuals. For healthy individuals with minor skin lesions, the use of the product may result in local infections, whereas in immunocompromised individuals the infection could spread into the blood stream, potentially leading to life-threatening sepsis. The products included in this expanded voluntary recall include: 4-N-1 is a no rinse wash cream intended to temporarily protect and help relieve chafed or cracked skin DermaCerin is a skin protectant moisturizing cream indicated to temporarily protect and help relieve dry, chapped, or cracked skin. It also helps protect skin from the drying effects of wind and cold weather. DermaFungal is an OTC antifungal cream intended for the treatment and prevention of most athlete's foot, jock itch, and ringworm. It relieves itching, scaling, cracking, and discomfort associated with these conditions. DermaKleen is an OTC healthcare antiseptic lotion soap with Vitamin E indicated for handwashing to decrease bacteria on the skin. DermaMed is an OTC skin protectant intended to dry the oozing and weeping of poison ivy, oak, or sumac, or other skin irritations. DermaSarra is an OTC external analgesic indicated for temporary relief of itching associated with minor skin irritations due to dry skin, insect bites, detergents, or sunburn. Gel Rite is an OTC instant gel hand sanitizer with vitamin E used to decrease bacteria on the skin. It is recommended for repeated use. Hand E Foam is an OTC foaming hand sanitizer with vitamin E used for handwashing to decrease bacteria on the skin. It is recommended for repeated use. KleenFoam is an OTC antimicrobial foam soap with Aloe Vera indicated for handwashing to decrease bacteria on the skin after changing diapers, after assisting ill people, or before contact with a person under medical care or treatment. Lantiseptic is an OTC skin protectant indicated to temporarily protect minor cuts, scrapes and burns. It helps prevent and temporarily protect chapped or cracked skin. PeriGiene is an OTC antiseptic cleanser indicated for use in the perineal area. PeriGuard is an OTC skin protectant indicated to help relieve and prevent rashes and irritation due to wetness from incontinence. It also protects chafed skin due to irritation and helps seal out wetness. Renew Dimethicone is an OTC skin protectant indicated to help treat and prevent diaper rash, protect minor skin irritations associated with diaper rash, and helps seal out wetness. Renew Periprotect is an OTC skin protectant indicated to help treat and prevent diaper rash, protect minor skin irritation associated with diaper rash, and helps seal out wetness. Renew Skin Repair is an OTC Skin cream indicated to temporarily protect and help relieve chapped or cracked skin. It is beneficial for face, hands, body and legs. UltraSure is an OTC anti-perspirant & deodorant indicated to reduce underarm wetness. The recalled products were distributed nationwide in the United States and in Puerto Rico. DermaRite has notified its distributors and customers by e-mail to immediately examine available inventory and destroy all affected products in accordance with each facility's process. Consumers with questions regarding this recall can call Sedgwick at 888-943-5190 Monday through Friday, 8:00 am – 5:00 pm EST or email [email protected] Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product or have questions about whether the product was used in their health care facility. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Recalled Product Information: Labels of affected products can be viewed here. SOURCE DermaRite WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

09 Aug 2025

·www.einpresswire.com

DermaRite Industries Issues Voluntary Nationwide Recall of DermaKleen, Dermasarra, Kleenfoam, and Perigiene Products Due to Burkholderia cepacia Contamination

COMPANY ANNOUNCEMENT When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Read Announcement View Product Photos Summary Company Announcement Date: August 08, 2025 FDA Publish Date: August 09, 2025 Product Type: Drugs Reason for Announcement: Recall Reason Description Contamination with Burkholderia cepacia Company Name: DermaRite Industries, LL Brand Name: Brand Name(s) DermaKleen, Dermasarra, Kleenfoam, and Perigiene Product Description: Product Description OTC antiseptic lotion soaps, external analgesics, antimicrobial foam soaps, and antiseptic cleansers Company Announcement DermaRite Industries, LLC is voluntarily recalling individual lots of products in the table below due to microbial contamination identified as Burkholderia cepecia. Risk Statement: Burkholderia Cepacia Complex in these products may result in serious and life-threatening infections. The contaminated products may be used by immunosuppressed individuals or by people attending to immunosuppressed individuals. In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis. To date, DermaRite has not received any reports of adverse events related to this recall. DermaKleen is an OTC Healthcare antiseptic lotion soap with Vitamin E indicated for handwashing to decrease bacteria on the skin. DermaSarra is an OTC External analgesic indicated for temporary relief of itching associated with minor skin irritations due to: dry skin, insect bites, detergents, sunburn. KleenFoam is an OTC Antimicrobial foam soap with Aloe Vera indicated for handwashing to decrease bacteria on the skin after changing diapers, after assisting ill people, or before contact with a person under medical care or treatment. PeriGiene is an OTC Antiseptic cleanser indicated for use in the perineal area. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information: (see Table image below) DermaRite has notified its distributors and customers by e-mail to immediately examine available inventory and destroy all affected products in accordance with each facility’s process. Consumers with questions regarding this recall can call Mary Goldberg at 973-569-9000 x104 Monday through Friday, 9:00 am – 5:00 pm EST or email voluntary.action@dermarite.com . Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Aloe vera extract

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Periodontitis	Phase 3	-	Dr. D.Y. Patil Medical College, Hospital & Research Centre	01 Feb 2014
radiation oral mucositis	Phase 2	Egypt	Minia University	01 Nov 2023
Cystitis, Interstitial	Phase 1	United States	Wake Forest School of Medicine	18 Feb 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Aloe vera extract

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation